VIVUS Announces New Data Demonstrating Effects Of Qsymia Capsules CIV

(RTTNews) - VIVUS, Inc. (VVUS) announced new results published online in Diabetes Care demonstrating the effects of Qsymia® capsules CIV, on the progression to type 2 diabetes.

Qsymia® capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The company noted that in the study, high-risk overweight or obese patients with prediabetes and/or metabolic syndrome who were taking Qsymia over a two year period experienced reductions of up to 78.7% in the annualized incidence rate of type 2 diabetes, in addition to losing weight.

Among patients in the study taking Qsymia, common adverse events included paraesthesia, sinusitis, dry mouth, constipation, headache, and dysgeusia. The types and severity of adverse events seen in this subgroup analysis were similar to those seen in the overall SEQUEL patient population and in other clinical trials.